{"id":62043,"date":"2026-04-19T19:08:14","date_gmt":"2026-04-19T17:08:14","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/leveraging-a-naturally-occurring-igm-autoantibody-to-target-diabetogenic-t-cells-a-precision-medicine-approach-to-type-1-diabetes\/"},"modified":"2026-04-19T19:08:14","modified_gmt":"2026-04-19T17:08:14","slug":"leveraging-a-naturally-occurring-igm-autoantibody-to-target-diabetogenic-t-cells-a-precision-medicine-approach-to-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/leveraging-a-naturally-occurring-igm-autoantibody-to-target-diabetogenic-t-cells-a-precision-medicine-approach-to-type-1-diabetes\/","title":{"rendered":"Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Apr 15;215(4):vkag056. doi: 10.1093\/jimmun\/vkag056.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Current immunotherapies for autoimmune diseases lack sufficient specificity and often compromise protective immunity, underscoring the need for precision-based approaches. Here, we identify x-mAb, a germline-encoded IgM autoantibody derived from dual-expresser lymphocytes of patients with type 1 diabetes (T1D), as a potent agent for precision immunotherapy. In the nonobese diabetic mouse model, x-mAb prevents disease onset, induces durable remission, and preserves functional pancreatic islets without disrupting systemic immune homeostasis. Mechanistically, x-mAb selectively targets islet-reactive CD4 and CD8 tissue-resident memory (Trm) T cells in pancreas and pancreatic lymph nodes, as shown by MHC tetramer staining and in vivo tracking. x-mAb engagement downregulates CD69, a key Trm retention molecule, resulting in a marked reduction of pathogenic pancreatic T cells. Critically, x-mAb recognizes analogous CD69+ Trm-like peripheral T cells in T1D patients and downregulates CD69 ex vivo, indicating a conserved and therapeutically targetable mechanism across species. Structural modeling revealed that x-mAb engages TCR\u03b1\u03b2 through multiple contact sites, with the most stable interactions targeting a conserved CDR3\u03b1 SGGGGS motif shared by diabetogenic human and mouse clonotypes. Based on these findings, we propose natural IgM autoantibodies as a previously unrecognized reservoir for precision biologics that selectively target autoreactive T cells while preserving immune competence.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41999654\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260419130812&amp;v=2.19.0.post6+133c1fe\">41999654<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag056\">10.1093\/jimmun\/vkag056<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Apr 15;215(4):vkag056. doi: 10.1093\/jimmun\/vkag056. ABSTRACT Current immunotherapies for autoimmune diseases lack sufficient specificity and often compromise protective immunity, underscoring the need for precision-based approaches. Here, we identify x-mAb, a germline-encoded IgM autoantibody derived from dual-expresser lymphocytes of patients with type 1 diabetes (T1D), as a potent agent for precision immunotherapy. In the &#8230; <a title=\"Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/19\/leveraging-a-naturally-occurring-igm-autoantibody-to-target-diabetogenic-t-cells-a-precision-medicine-approach-to-type-1-diabetes\/\" aria-label=\"Read more about Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-62043","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=62043"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62043\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=62043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=62043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=62043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}